Skip to main navigation Skip to main content

Clin Mol Hepatol : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Articles

Editorial

ASB3 degrades the gateway to β-oxidation: Editorial on “Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates metabolic dysfunction-associated steatotic liver disease by decreasing ubiquitin-mediated carnitine palmitoyl transferase 1A”

Clinical and Molecular Hepatology 2026;32(3):1379-1382.
Published online: September 23, 2025

1College of Pharmacy, Seoul National University, Seoul, Korea

2Research Institute of Pharmaceutical Sciences and Natural Products Research Institute, Seoul National University, Seoul, Korea

Corresponding author : Ja Hyun Koo, College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Korea Tel: +82-2-880-8586, E-mail: jhkoo@snu.ac.kr

Editor: Han Ah Lee, Chung-Ang University College of Medicine, Korea

• Received: September 9, 2025   • Accepted: September 17, 2025

Copyright © 2026 by The Korean Association for the Study of the Liver

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 2,690 Views
  • 169 Download
  • 1 Web of Science
  • 2 Crossref
  • 1 Scopus
prev next

Citations

Citations to this article as recorded by  Crossref logo
  • TREM1-mediated macrophage activation drives voriconazole-induced hepatic steatosis: Diagnostic and therapeutic implications
    Jing Liu, Mingxia Deng, Xiaoying He, Jing Ma, Li Zhang, Xi Yang, Jinyao Dai, Shaohua Dong, Yichun Zhang, Zhijuan Zhang, Shuaibing Ying, Haoyang Hu, Lushun Jiang, Yujing Wang, Yunqing Qiu, Yan Lou
    Journal of Pharmaceutical Analysis.2026; 16(6): 101540.     CrossRef
  • Correspondence to editorial 2 on “Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates metabolic dysfunction-associated steatotic liver disease by decreasing ubiquitin-mediated carnitine palmitoyl transferase 1A”
    Dongqin Yang, Yuli Lin, Chunhua Song, Ming Guan
    Clinical and Molecular Hepatology.2026; 32(3): e342.     CrossRef

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

Include:

ASB3 degrades the gateway to β-oxidation: Editorial on “Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates metabolic dysfunction-associated steatotic liver disease by decreasing ubiquitin-mediated carnitine palmitoyl transferase 1A”
Clin Mol Hepatol. 2026;32(3):1379-1382.   Published online September 23, 2025
Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:
Include:
ASB3 degrades the gateway to β-oxidation: Editorial on “Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates metabolic dysfunction-associated steatotic liver disease by decreasing ubiquitin-mediated carnitine palmitoyl transferase 1A”
Clin Mol Hepatol. 2026;32(3):1379-1382.   Published online September 23, 2025
Close

Figure

  • 0
ASB3 degrades the gateway to β-oxidation: Editorial on “Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates metabolic dysfunction-associated steatotic liver disease by decreasing ubiquitin-mediated carnitine palmitoyl transferase 1A”
Image
Figure 1. ASB3 promotes degradation of CPT1A by ubiquitination, impeding hepatic fatty acid oxidation in MASLD. CPT1A facilitates the mitochondrial import of fatty acids by transferring the acyl group from acyl-CoA to L-carnitine. Within mitochondria, acyl-carnitine is reconverted to acyl-CoA and subjected to β-oxidation, with the resulting products further oxidized in the tricarboxylic acid cycle. In the livers of MASLD patients and diet-induced MASLD model mice, ASB3 expression is upregulated, promoting ubiquitination and proteasomal degradation of CPT1A. This process compromises mitochondrial fatty acid import and lipid catabolism. Given the reported role of CPT1A in mitochondrial dynamics, its degradation may further impair mitochondrial fission and quality control mechanisms. ASB3, ankyrin repeat and SOCS box protein 3; CPT1A, carnitine palmitoyltransferase 1A; MASLD, metabolic dysfunction-associated steatotic liver disease; TCA, tricarboxylic acid; MCD, methionine/choline deficient; GAN, Gubra Amylin nonalcoholic steatohepatitis.
ASB3 degrades the gateway to β-oxidation: Editorial on “Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates metabolic dysfunction-associated steatotic liver disease by decreasing ubiquitin-mediated carnitine palmitoyl transferase 1A”